{"id":61940,"date":"2026-03-31T14:01:41","date_gmt":"2026-03-31T06:01:41","guid":{"rendered":"https:\/\/flcube.com\/?p=61940"},"modified":"2026-03-31T14:01:42","modified_gmt":"2026-03-31T06:01:42","slug":"nmpa-expands-generic-quality-consistency-evaluation-program-with-36-new-reference-drug-specifications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61940","title":{"rendered":"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications"},"content":{"rendered":"\n<p>China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has released its <strong>103rd batch of reference drugs<\/strong> for the <strong>Generic Quality Consistency Evaluation (GQCE)<\/strong> program, adding <strong>36 specifications<\/strong> to strengthen quality standards for generic medications in the Chinese market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-update-summary\">Regulatory Update Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Program<\/strong><\/td><td>Generic Quality Consistency Evaluation (GQCE)<\/td><\/tr><tr><td><strong>Batch Number<\/strong><\/td><td>103rd<\/td><\/tr><tr><td><strong>Total New Specifications<\/strong><\/td><td>36<\/td><\/tr><tr><td><strong>New Reference Drugs<\/strong><\/td><td>23 specifications<\/td><\/tr><tr><td><strong>Modified Specifications<\/strong><\/td><td>13 specifications<\/td><\/tr><tr><td><strong>Release Date<\/strong><\/td><td>31 Mar 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-context-amp-strategic-importance\">Program Context &amp; Strategic Importance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GQCE Initiative:<\/strong> Launched in 2016 to ensure domestic generic drugs demonstrate therapeutic equivalence to original branded products or internationally recognized reference medications.<\/li>\n\n\n\n<li><strong>Quality Assurance:<\/strong> The reference drug list provides clear benchmarks for manufacturers to develop higher-quality generics that meet rigorous scientific standards.<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Products successfully completing GQCE gain preferential treatment in public procurement programs and hospital formularies.<\/li>\n\n\n\n<li><strong>International Alignment:<\/strong> The program aligns China&#8217;s pharmaceutical standards with global best practices, facilitating international market access for compliant manufacturers.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-impact-analysis\">Industry Impact Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Domestic Manufacturers<\/strong><\/td><td>Clear regulatory pathway to develop and register generic alternatives meeting international quality standards<\/td><\/tr><tr><td><strong>Healthcare System<\/strong><\/td><td>Improved therapeutic outcomes through consistent medication performance across branded and generic options<\/td><\/tr><tr><td><strong>Market Competition<\/strong><\/td><td>Increased competition among manufacturers who can demonstrate quality equivalence<\/td><\/tr><tr><td><strong>Regulatory Evolution<\/strong><\/td><td>Modified specifications reflect updated scientific understanding and evolving international standards<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The addition of these 36 specifications demonstrates China&#8217;s continued commitment to pharmaceutical quality reform. The inclusion of 13 modified specifications suggests ongoing refinement of the reference standards based on emerging scientific evidence and international harmonization efforts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Momentum:<\/strong> Expect accelerated GQCE approvals throughout 2026 as China continues strengthening its pharmaceutical regulatory framework.<\/li>\n\n\n\n<li><strong>Manufacturing Investment:<\/strong> Domestic companies are likely to increase R&amp;D investment to meet GQCE requirements for high-value generic products.<\/li>\n\n\n\n<li><strong>Global Implications:<\/strong> International pharmaceutical firms benefit from greater transparency regarding quality benchmarks in the Chinese market.<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Enhanced quality standards combined with generic competition should improve patient access to affordable, reliable medications.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory developments and market implications related to China&#8217;s GQCE program. Actual outcomes may differ due to policy changes, implementation challenges, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[31,14],"class_list":["post-61940","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-generic-drugs","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for the Generic Quality Consistency Evaluation (GQCE) program, adding 36 specifications to strengthen quality standards for generic medications in the Chinese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61940\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for the Generic Quality Consistency Evaluation (GQCE) program, adding 36 specifications to strengthen quality standards for generic medications in the Chinese market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61940\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T06:01:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T06:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61940#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61940\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications\",\"datePublished\":\"2026-03-31T06:01:41+00:00\",\"dateModified\":\"2026-03-31T06:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61940\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Generic drugs\",\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61940#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61940\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61940\",\"name\":\"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-31T06:01:41+00:00\",\"dateModified\":\"2026-03-31T06:01:42+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for the Generic Quality Consistency Evaluation (GQCE) program, adding 36 specifications to strengthen quality standards for generic medications in the Chinese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61940#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61940\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61940#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for the Generic Quality Consistency Evaluation (GQCE) program, adding 36 specifications to strengthen quality standards for generic medications in the Chinese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61940","og_locale":"en_US","og_type":"article","og_title":"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications","og_description":"China's National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for the Generic Quality Consistency Evaluation (GQCE) program, adding 36 specifications to strengthen quality standards for generic medications in the Chinese market.","og_url":"https:\/\/flcube.com\/?p=61940","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T06:01:41+00:00","article_modified_time":"2026-03-31T06:01:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61940#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61940"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications","datePublished":"2026-03-31T06:01:41+00:00","dateModified":"2026-03-31T06:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61940"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Generic drugs","NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61940#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61940","url":"https:\/\/flcube.com\/?p=61940","name":"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-31T06:01:41+00:00","dateModified":"2026-03-31T06:01:42+00:00","description":"China's National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for the Generic Quality Consistency Evaluation (GQCE) program, adding 36 specifications to strengthen quality standards for generic medications in the Chinese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61940#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61940"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61940#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61940"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61940\/revisions"}],"predecessor-version":[{"id":61943,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61940\/revisions\/61943"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}